- The FDA’s Vaccine Advisory Committee is meeting Friday to discuss the need for booster shots of Johnson & Johnson’s COVID-19 vaccine.
- NIH plans to submit data showing higher antibody levels to J&J recipients if they get a booster shot from Pfizer or Moderna
- It is not clear what size dose the patients received or how long the immune response will last.
- J&J has asked the FDA to approve a shot of its own single-dose vaccine as a booster dose
People receiving Johnson & Johnson’s COVID-19 vaccine have higher antibody levels if their booster shot is from Pfizer-BioNtech or Moderna, a new report suggests.
The National Institutes of Health (NIH) has reportedly collected data showing that mix-and-match is more protective than receiving two doses from a New Brunswick, New Jersey-based company, a person who viewed the data said. Told axios.
NIH officials plan to present the findings during a meeting of the US Food and Drug Administration (FDA) Vaccine Advisory Committee on Friday.
It comes as J&J has asked the FDA to approve a single shot of its single-dose vaccine as a booster dose.
The FDA’s Vaccine Advisory Committee is meeting Friday to discuss the need for booster shots of Johnson & Johnson’s COVID-19 vaccine. Image: Diana Cerlo, a retired registered nurse from Excella, administers a COVID-19 vaccine booster shot in North Huntington, Pennsylvania in September 2021
The NIH plans to present data showing that J&J recipients have higher antibody levels if they get a booster shot from Pfizer or Moderna. Image: Vials of Pfizer-BioNtech and Moderna COVID-19 Vaccines, February 2021
According to Axios, NIH data are considered to show a “significantly stronger neutralizing antibody response” from Pfizer or Moderna Booster than from a second dose of J&J.
It is not currently clear whether recipients have received a full or half dose of the booster shot and how long after their first shot they have received the booster.
However, according to the report, the NIH data had limitations.
Neutralizing antibodies are just the type of immune response, preventing the virus from entering cells and replicating, and the report said it was unclear how long the response would last.
The NIH, FDA and J&J did not immediately respond to DailyMail.com’s requests for comment.
As of Wednesday, about 15.2 million Americans have received the J&J vaccine, which is administered as a single dose.
J&J has asked the FDA to approve one shot of its single-dose vaccine as a booster dose. Image: Vials of J&J COVID-19 vaccine at a pharmacy in Denver in October 2021
Last month, the firm published the results of a study looking at an additional second shot of its vaccine.
Phase III, a two-dose trial of 30,000 participants, looked at the effectiveness of a second dose 56 days after the first dose in adults 18 years of age and older.
The results showed that the booster shot was 94 percent effective against symptomatic COVID-19 in the US and 100 percent effective against severe disease at least 14 days after vaccination.
This compares to the 70 percent protection seen with a single dose.
There was only one case of COVID-19 in the vaccine group and 14 in the placebo group.
J&J said boosters given two months after the first dose increased antibody levels between four-fold and six-fold.
When given six months after the first dose, antibody levels increased nine-fold after one week and 12-fold after four weeks.
These increases were observed regardless of age.
Side effects of the two doses were comparable to those seen in studies with the single-dose vaccine.
“A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides robust and long-lasting protection, will help the global population,” said Dr Paul Stoffels, J&J’s Chief Scientific Officer. Getting vaccinated is important. Statement those days.
‘At the same time, we have now produced evidence that a booster shot further enhances protection against COVID-19 and is expected to substantially extend the duration of protection.’
This week, the FDA advisory committee will also meet this week to discuss the need for an additional dose of Moderna’s vaccine.
FDA scientists have said Moderna did not meet all of the agency’s criteria to support the use of a booster dose of its COVID-19 vaccine, possibly because the efficacy of the first two doses of the shot remains strong.